Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.02.02.703356

Embarrassingly_FASTA: Enabling Recomputable, Population-Scale Pangenomics by Reducing Commercial Genome Processing Costs from $100 to less than $1

Abstract

Computational preprocessing has become the dominant bottleneck in genomics, frequently exceeding sequencing costs and constraining population-scale analysis, even as large repositories grow from tens of petabytes toward exabyte-scale storage to support World Genome Models. Legacy CPU-based workflows require many hours to days per 30x human genome, driving many repositories to distribute aligned or derived intermediates such as BAM and VCF files rather than raw FASTQ data. These intermediates embed reference- and model-dependent assumptions that limit reproducibility and impede reanalysis as reference genomes, including pangenomes, continue to evolve. Although recent work has established that GPUs can dramatically accelerate genomic pipelines, enabling large-cohort processing to shrink from years to days given sufficient parallelism, such workflows remain cost-prohibitive. Here, we introduce Embarrassingly_FASTA, a GPU-accelerated preprocessing pipeline built on NVIDIA Parabricks that fundamentally changes the economics of genomic data management. By rendering intermediate files transient rather than archival, Embarrassingly_FASTA enables retention of raw FASTQ data and reliable use of highly discounted ephemeral cloud infrastructure such as spot instances, reducing compute spend from [~]$17/genome (CPU on-demand) to <$1/genome (GPU spot), and commercial secondary-analysis pricing from [~]$120/genome to compute spend under $1/genome. We demonstrate the impact of this efficiency using a simulated large-cohort pangenome build-up (using variant-union accumulation as a proxy for diversity growth) in Caenorhabditis elegans and humans, highlighting the long tail of unsampled human genetic diversity. Beyond GPU kernels, Embarrassingly_FASTA contributes a transient-intermediate lifecycle and spot-friendly orchestration that makes FASTQ retention and routine recomputation economically viable. Embarrassingly_FASTA thus provides enabling infrastructure for recomputable, population-scale pangenomics and next-generation genomic models. Non-Expert DescriptionReading a persons complete DNA sequence has become fast and inexpensive, but turning that raw data into something scientists can analyze is now one of the biggest obstacles in modern genetics. Today, processing a single genome can take many hours or even days, which makes it difficult and expensive to study large populations or reanalyze data when better methods become available. As a result, many databases store only partially processed DNA instead of the original data, limiting future discoveries. In this work, we present a new system that dramatically speeds up this processing step using graphics processing units (GPUs), the same type of hardware used in modern artificial intelligence. With our approach, a human genome can be processed in about 35 minutes instead of more than 15 hours, and at a fraction of the cost. This makes it practical to keep the original DNA data and reprocess it whenever new tools or reference genomes become available, rather than being locked into outdated results. We also show that this speed and affordability allow researchers to explore genetic diversity at an unprecedented scale. By analyzing both human genomes and those of a small worm species commonly used in research, we demonstrate how new genetic variations continue to emerge as more individuals are studied, especially in humans, where much diversity remains unexplored. Overall, our work helps remove a major barrier to studying DNA at population scale and lays the foundation for future genetic models that could better explain disease, evolution, and human health. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=112 SRC="FIGDIR/small/703356v2_ufig1.gif" ALT="Figure 1"> View larger version (69K): org.highwire.dtl.DTLVardef@11b8fc3org.highwire.dtl.DTLVardef@7b8b60org.highwire.dtl.DTLVardef@fb5a3borg.highwire.dtl.DTLVardef@1e11276_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Walsh, D. J., Njie, e. G.. 2026-02-04. Embarrassingly_FASTA: Enabling Recomputable, Population-Scale Pangenomics by Reducing Commercial Genome Processing Costs from $100 to less than $1. https://doi.org/10.64898/2026.02.02.703356

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗